<PAGE> 1
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q
[X] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the quarterly period ended June 30, 1997
[ ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
For the transaction period from __________ to __________
Commission file number 0-19267
ALKERMES, INC.
----------------------------------------------------
(Exact name of registrant as specified in its charter)
PENNSYLVANIA 23-2472830
- ------------------------------------------ --------------------------
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
64 Sidney Street, Cambridge, MA 02139-4136
- ------------------------------------------ --------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number including area code: (617) 494-0171
------------------------------
NOT APPLICABLE
- --------------------------------------------------------------------------------
Former name, former address, and former fiscal year, if changed since last
report
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
----- -----
Indicate the number of shares outstanding of each of the issuer's classes
of common stock, as of the latest practicable date.
Class Shares Outstanding as of August 7, 1997
----- ---------------------------------------
Common Stock, par value $.01 20,789,589
<PAGE> 2
ALKERMES, INC. AND SUBSIDIARIES
INDEX
PAGE NO.
--------
PART I - FINANCIAL INFORMATION
Item 1. Consolidated Financial Statements
Consolidated Balance Sheets 3
- June 30, 1997 and March 31, 1997
Consolidated Statements of Operations 4
- Three months ended June 30, 1997 and 1996
Consolidated Statement of Shareholders' Equity 5
- Three months ended June 30, 1997
Consolidated Statements of Cash Flows 6
- Three months ended June 30, 1997 and 1996
Notes to Consolidated Financial Statements 7
Item 2. Management's Discussion and Analysis of 8
Financial Condition and Results of Operations
PART II - OTHER INFORMATION
Item 4. Submission of Matters to a Vote of Security Holders 11
Item 6. Exhibits and Reports on Form 8-K 12
SIGNATURES 14
EXHIBIT INDEX 15
(2)
<PAGE> 3
ITEM 1. CONSOLIDATED FINANCIAL STATEMENTS:
ALKERMES, INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(Unaudited)
<TABLE>
<CAPTION>
June 30, March 31,
1997 1997
------------- -------------
ASSETS
<S> <C> <C>
Current Assets:
Cash and cash equivalents $ 4,016,171 $ 2,799,012
Short-term investments 81,630,374 82,497,939
Prepaid expenses and other current assets 4,275,387 4,571,089
------------- -------------
Total current assets 89,921,932 89,868,040
------------- -------------
Property, Plant and Equipment:
Land 225,000 225,000
Building 1,275,000 1,275,000
Furniture, fixtures and equipment 12,934,809 11,963,945
Leasehold improvements 2,257,069 2,183,280
Construction in progress 201,268 90,000
------------- -------------
16,893,146 15,737,225
Less accumulated depreciation and amortization (8,018,318) (7,289,446)
------------- -------------
8,874,828 8,447,779
------------- -------------
Investments 1,362,559 5,366,291
------------- -------------
Other Assets 553,231 582,732
------------- -------------
Other Investments 469,674 432,176
------------- -------------
$ 101,182,224 $ 104,697,018
============= =============
LIABILITIES AND SHAREHOLDERS' EQUITY
Current Liabilities:
Accounts payable and accrued expenses $ 3,127,718 $ 4,653,081
Long-term obligations--current portion 3,772,942 3,547,542
------------- -------------
Total current liabilities 6,900,660 8,200,623
------------- -------------
Long-Term Obligations 12,210,082 10,914,127
------------- -------------
Other Long-Term Liabilities 1,623,379 1,430,832
------------- -------------
Deferred Revenue 5,000,000 5,000,000
------------- -------------
Shareholders' Equity:
Capital stock, par value $.01 per share:
Authorized, 5,000,000 shares; none issued
Common stock, par value $.01 per share:
Authorized 40,000,000 shares; issued 20,775,840 shares at
June 30, 1997 and 20,718,790 shares at March 31, 1997 207,759 207,188
Additional paid-in capital 199,105,852 198,844,191
Deferred compensation (94,287) (109,901)
Cumulative foreign currency translation adjustments (7,816) (16,869)
Unrealized gain on marketable securities 108,750 71,250
Accumulated deficit (123,872,155) (119,844,423)
------------- -------------
Total shareholders' equity 75,448,103 79,151,436
------------- -------------
$ 101,182,224 $ 104,697,018
============= =============
</TABLE>
See notes to consolidated financial statements.
(3)
<PAGE> 4
ALKERMES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Three Months
Ended Ended
June 30, June 30,
1997 1996
------------ -----------
<S> <C> <C>
Revenues:
Research and development revenue under
collaborative arrangements $ 4,781,843 $ 2,476,909
Research and development revenue under
collaborative arrangement with related party -- 1,415,313
Interest income 1,149,554 527,728
----------- -----------
5,931,397 4,419,950
----------- -----------
Expenses:
Research and development 7,607,927 6,613,399
General and administrative 1,914,020 2,443,131
Interest expense 437,182 307,411
----------- -----------
9,959,129 9,363,941
----------- -----------
Net loss $(4,027,732) $(4,943,991)
=========== ===========
Net loss per weighted average number of common
shares $ (0.19) $ (0.29)
=========== ===========
Weighted average number of common shares
outstanding 20,752,848 17,325,561
=========== ===========
</TABLE>
See notes to consolidated financial statements.
(4)
<PAGE> 5
ALKERMES, INC. AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY
(Unaudited)
<TABLE>
<CAPTION>
Additional
Common Stock Paid-in Deferred
Shares Amount Capital Compensation
------ ------ ------- ------------
<S> <C> <C> <C> <C>
Balance, April 1, 1997 20,718,790 $207,188 $198,844,191 $(109,901)
Issuance of common stock 4/97 through 6/97 57,050 571 261,661 --
Amortization of compensation relating to grant
of stock options and awards made -- -- -- 15,614
Unrealized gain on marketable securities -- -- -- --
Cumulative foreign currency translation adjustments -- -- -- --
Net loss for period -- -- -- --
---------- -------- ------------ ---------
Balance, June 30, 1997 20,775,840 $207,759 $199,105,852 $ (94,287)
========== ======== ============ =========
</TABLE>
<TABLE>
<CAPTION>
Cumulative Unrealized
Foreign Currency Gain
Translation on Marketable Accumulated
Adjustments Securities Deficit Total
----------- ---------- ------- -----
<S> <C> <C> <C> <C>
Balance, April 1, 1997 $(16,869) $ 71,250 $(119,844,423) $ 79,151,436
Issuance of common stock 4/97 through 6/97 -- -- -- 262,232
Amortization of compensation relating to grant
of stock options and awards made -- -- -- 15,614
Unrealized gain on marketable securities -- 37,500 -- 37,500
Cumulative foreign currency translation adjustments 9,053 -- -- 9,053
Net loss for period -- -- (4,027,732) (4,027,732)
-------- -------- ------------- ------------
Balance, June 30, 1997 $ (7,816) $108,750 $(123,872,155) $ 75,448,103
======== ======== ============= ============
</TABLE>
See notes to consolidated financial statements.
(5)
<PAGE> 6
ALKERMES, INC. AND SUBSIDIARIES
STATEMENTS OF CASH FLOWS
(Unaudited)
<TABLE>
<CAPTION>
Three Months Three Months
Ended Ended
June 30, June 30,
1997 1996
------------ -------------
<S> <C> <C>
Cash flows from operating activities:
Net loss $(4,027,732) $ (4,943,991)
Adjustments to reconcile net loss to net cash used by
operating activities:
Depreciation and amortization 769,938 570,772
Amortization of amounts receivable for warrants and compensation
relating to grant of stock options and awards made 15,614 77,961
Adjustments to other investments 2 13,585
Changes in assets and liabilities:
Prepaid expenses and other current assets 294,605 (394,631)
Accounts payable and accrued expenses (1,522,399) (1,328,656)
Other long-term liabilities 192,547 128,196
----------- ------------
Net cash used by operating activities (4,277,425) (5,876,764)
----------- ------------
Cash flows from investing activities:
Additions to property, plant and equipment, net (1,162,572) (486,563)
Sales (purchases) of short-term investments, net 867,565 (15,940,210)
Sales (purchases) of investments, net 4,003,732 (8,044)
Other assets (8,000) --
----------- ------------
Net cash provided by (used by) investing activities 3,700,725 (16,434,817)
----------- ------------
Cash flows from financing activities:
Proceeds from issuance of common stock, net 262,232 23,370,753
Proceeds from issuance of long-term debt 2,500,000 --
Payment of long-term obligations (978,274) (728,337)
----------- ------------
Net cash provided by financing activities 1,783,958 22,642,416
----------- ------------
Effect of exchange rate changes on cash 9,901 7,254
----------- ------------
Net increase in cash and cash equivalents 1,217,159 338,089
Cash and cash equivalents, beginning of period 2,799,012 445,150
----------- ------------
Cash and cash equivalents, end of period $ 4,016,171 $ 783,239
=========== ============
Supplementary information:
Interest paid $ 217,733 $ 234,409
=========== ============
</TABLE>
See notes to consolidated financial statements.
(6)
<PAGE> 7
ALKERMES, INC. AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
1. BASIS OF PRESENTATION
The consolidated financial statements for the three month periods ended June 30,
1997 and 1996, are unaudited and include all adjustments which, in the opinion
of management, are necessary to present fairly the results of operations for the
periods then ended. All such adjustments are of a normal recurring nature. These
financial statements should be read in conjunction with the Company's Annual
Report on Form 10-K for the year ended March 31, 1997, which includes
consolidated financial statements and notes thereto for the years ended March
31, 1997, 1996 and 1995. In addition, the financial statements include the
accounts of Alkermes Controlled Therapeutics, Inc., Alkermes Controlled
Therapeutics Inc. II, Alkermes Investments, Inc., Alkermes Europe, Ltd. and
Alkermes Development Corporation II ("ADC II"), wholly owned subsidiaries of the
Company.
The results of the Company's operations for any interim period are not
necessarily indicative of the results of the Company's operations for any other
interim period or for a full fiscal year.
The preparation of the Company's financial statements in conformity with
generally accepted accounting principles necessarily requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenues and expenses
during the reporting period. Actual results could differ from those estimates.
2. NEW ACCOUNTING PRONOUNCEMENT
In February 1997, the Financial Accounting Standards Board issued Statement of
Financial Accounting Standards ("SFAS") No. 128, "Earnings per Share," which the
Company is required to adopt in the quarter ending December 31, 1997. SFAS No.
128 requires companies to change the method currently used to compute earnings
per share and to restate all prior periods for comparability. The adoption of
SFAS No. 128 is not expected to have any impact on the Company's consolidated
financial statements because the Company continues to be in a net loss position
and, consequently, common equivalent shares from stock options and warrants are
excluded as their effect is antidilutive.
3. LONG-TERM DEBT
In June 1997, the Company amended its loan agreement with a bank to increase the
principal amount of the loan thereunder by $2,500,000 and to grant a security
interest in certain equipment as security for the entire principal of, and
interest on, the loan. The additional principal amount of the loan is payable
over five years in equal monthly installments of $41,667, which commenced July
1, 1997 and bears interest at the fixed rate of 8.58% per annum.
(7)
<PAGE> 8
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
INTRODUCTION
Alkermes is developing innovative pharmaceutical products based on three
proprietary drug delivery systems: ProLease(R), RMP-7(TM) and Medisorb(R). Since
its inception in 1987, the Company has devoted substantially all of its
resources to its research and development programs. Alkermes has not received
any revenue from the sales of products. The Company has been unprofitable since
inception and expects to incur substantial additional operating losses over the
next several years. At June 30, 1997, the Company had an accumulated deficit of
approximately $123.9 million.
The Company has funded its operations primarily through public offerings and
private placements of equity securities, bank loans and payments under research
and development agreements with collaborators, including Alkermes Clinical
Partners, L.P. ("Clinical Partners"), a research and development limited
partnership of which ADC II serves as the one percent general partner. The
Company intends to develop its product candidates in collaboration with others
on whom the Company will rely for funding, development, manufacturing and/or
marketing.
FORWARD-LOOKING STATEMENTS
Any statements set forth below or otherwise made in writing or orally by the
Company with regard to its expectations as to financial results and other
aspects of its business may constitute forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995. Although the
Company makes such statements based on assumptions which it believes to be
reasonable, the Company's business is subject to significant risks and there can
be no assurance that actual results will not differ materially from the
Company's expectations. Accordingly, the Company hereby identifies the following
important factors, among others, which could cause its results to differ from
any results which might be projected, forecasted or estimated by the Company in
any such forward-looking statements: (i) the Company and its collaborators could
not be permitted by regulatory authorities to undertake additional clinical
trials for ProLease, RMP-7 or Medisorb product candidates; (ii) product
candidates could be ineffective or unsafe during clinical trials; (iii) the
Company could incur difficulties or set-backs in obtaining the substantial
additional funding required to continue research and development programs and
clinical trials; (iv) even if product candidates appear promising at an early
stage of development, product candidates could fail to receive necessary
regulatory approvals, be difficult to manufacture on a large scale, be
uneconomical, fail to achieve market acceptance, be precluded from
commercialization by proprietary rights of third parties or experience
substantial competition in the marketplace; (v) technological change in the
biotechnology or pharmaceutical industries could render the Company's product
candidates obsolete or noncompetitive; (vi) disputes with collaborators,
termination of collaborations or failure to negotiate acceptable new
collaborative arrangements for ProLease and Medisorb technologies, which are not
independently commercializable, could occur; (vii) disputes with Clinical
Partners over rights to the RMP-7 and related technology could occur, or the
Company could fail to purchase this technology from the Limited Partners of
Clinical Partners pursuant to the purchase option (the "Purchase Option"), or,
if the Company did purchase RMP(TM) technology from the Limited Partners (a) in
shares of the Company's common stock, the Company's shareholders would be
substantially diluted or (b) in cash, the Company's capital resources would be
significantly depleted; and (viii) difficulties or set-backs in obtaining and
enforcing Alkermes' patents and difficulties with the patent rights of others
could occur.
(8)
<PAGE> 9
RESULTS OF OPERATIONS
The Company's research and development revenue under collaborative arrangements
for the three months ended June 30, 1997 was $4,781,843 compared to $2,476,909
for the corresponding period of the prior year. The increase in such revenue for
the three months ended June 30, 1997 as compared to the corresponding period of
the prior year was mainly a result of the increased funding earned under
collaborative agreements related to the Company's ProLease and Medisorb
technologies. The Company's research and development revenue under collaborative
arrangement with related party for the three months ended June 30, 1997 was zero
compared to $1,415,313 for the corresponding period of the prior year. This
revenue was received from Clinical Partners under a product development
agreement entered into in March 1992. The decrease in such revenue for the three
months ended June 30, 1997 as compared to the corresponding period of the prior
year was a result of the completion of the development funding under the product
development agreement with Clinical Partners during the quarter ended June 30,
1996.
Interest income for the three months ended June 30, 1997 was $1,149,554 compared
to $527,728 for the corresponding period of the prior year. The increase in such
revenue for the three months ended June 30, 1997 as compared to the
corresponding period of the prior year was primarily a result of the interest
income earned on the net proceeds of $49.7 million from the sale of 2,000,000
shares of the Company's common stock to ALZA Corporation in March 1997.
The Company's total operating expenses were $9,959,129 for the three months
ended June 30, 1997 as compared to $9,363,941 for the three months ended June
30, 1996. Research and development expenses for the three months ended June 30,
1997 were $7,607,927 compared to $6,613,399 for the corresponding period of the
prior year. The increase in research and development expenses for the three
months ended June 30, 1997 as compared to the three months ended June 30, 1996
was mainly the result of an increase in salary and related benefits and other
costs associated with an increase in personnel as the Company advances its
product candidates through development and clinical trials and prepares for
large-scale product scale-up and process development.
General and administrative expenses for the three months ended June 30, 1997
were $1,914,020 compared to $2,443,131 for the corresponding period of the prior
year. The decrease in the three months ended June 30, 1997 as compared to the
three months ended June 30, 1996 was mainly the result of non-cash charges
related to the write-down of the Company's investment in Clinical Partners which
was recorded in the three months ended June 30, 1996. The decrease was partially
offset by an increase in salary and related benefits and patent legal costs
incurred during the three months ended June 30, 1997.
The Company does not believe that inflation and changing prices have had a
material impact on its results of operations.
(9)
<PAGE> 10
LIQUIDITY AND CAPITAL RESOURCES
At June 30, 1997, the Company had current assets totaling $89,921,932, primarily
consisting of $4,016,171 in cash and cash equivalents and $81,630,374 in U.S.
Government obligations having a maturity of less than one year; and current
liabilities of $6,900,660. The Company's short-term investment objectives are,
first, to assure conservation of principal, and second, to obtain investment
income. As a result, the Company invests primarily in high grade government or
government-backed securities.
The Company's research and development costs to date have been financed
primarily by sales of equity securities and funding from research and
development collaborative arrangements. The Company expects to incur significant
research and development and other costs, including costs related to preclinical
studies, clinical trials and facilities expansion. Since the research and
development revenue from Clinical Partners ended during the quarter ended June
30, 1996, Alkermes has been using and intends to continue to use its own
resources to continue to develop RMP-7. The Company is required to fund the
development of RMP-7 to maintain its option to purchase the Limited Partners'
interests in Clinical Partners. Therefore, the Company expects that its costs,
including research and development costs for all of its product candidates, will
exceed revenues significantly for the next several years, which will result in
continuing losses from operations.
The Company expects to begin construction of a new commercial scale ProLease
manufacturing facility in Cambridge, Massachusetts during fiscal 1998. The
Company also expects to begin an expansion of its Medisorb manufacturing
facility in Wilmington, Ohio during fiscal 1998. The total cost for both
facilities is expected to be approximately $15 to $20 million. The Company's
capital expenditures for equipment, facilities and building improvements have
been financed to date primarily with proceeds from bank loans and the sales of
equity securities. The Company will continue to pursue opportunities to obtain
additional financing in the future. Such financing may be sought through various
sources, including equity offerings, bank borrowings, lease arrangements
relating to fixed assets or other financing methods. The source, timing and
availability of any financings will depend on market conditions, interest rates
and other factors.
The Company's future capital requirements will depend on many factors, including
continued scientific progress in its research and development programs, the
magnitude of these programs, progress with preclinical testing and clinical
trials, the time and costs involved in obtaining regulatory approvals, the costs
involved in filing, prosecuting and enforcing patent claims, competing
technological and market developments, the establishment of additional
collaborative arrangements, the cost of manufacturing facilities and of
commercialization activities and arrangements and the cost of product
in-licensing and any possible acquisitions.
The Company will need to raise substantial additional funds for longer-term
product development, regulatory approvals and manufacturing or marketing
activities that it might undertake in the future. There can be no assurance that
additional funds will be available on favorable terms, if at all. If adequate
funds are not available, the Company may be required to curtail significantly
one or more of its research and development programs and/or obtain funds through
arrangements with collaborative partners or others that may require the Company
to relinquish rights to certain of its technologies, product candidates or
future products.
(10)
<PAGE> 11
PART II. OTHER INFORMATION
ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS
At the Annual Meeting of Shareholders of the Registrant held on July 25, 1997,
the holders of Common Stock approved the amendment to the Alkermes Amended and
Restated 1990 Omnibus Stock Option Plan, as amended, to increase to 2,500,000
the number of shares issuable upon the exercise of options granted thereunder,
an increase of 750,000 shares. There were 14,196,795 votes for, and 3,895,177
votes against, the adoption, 96,565 broker non-votes and 121,743 abstentions.
Also at the Annual Meeting of Shareholders, the holders of Common Stock elected
the following as directors for terms of one year expiring on the date of the
1998 annual meeting or until their respective successors are duly elected and
shall qualify:
<TABLE>
<CAPTION>
Votes Authority
Nominee For Withheld
- ------- --- --------
<S> <C> <C>
Floyd E. Bloom 17,376,914 933,366
---------- -------
Robert A. Breyer 17,497,839 812,441
---------- -------
John K. Clarke 17,501,014 809,266
---------- -------
Robert S. Langer 17,376,964 933,316
---------- -------
Richard F. Pops 17,501,664 808,616
---------- -------
Alexander Rich 17,377,546 932,734
---------- -------
Paul Schimmel 17,378,064 932,216
---------- -------
Michael A. Wall 17,377,914 932,366
---------- -------
</TABLE>
(11)
<PAGE> 12
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) Exhibits:
NUMBER EXHIBIT
------ -------
3.1(a) Second Amended and Restated Articles of
Incorporation, as filed with the Pennsylvania
Secretary of State on July 23, 1991 (Incorporated
by reference to Exhibit 4.1(a) to the Company's
Report on Form 10-Q for the quarter ended June 30,
1991).
3.1(b) Statement of Change of Registered Office, as filed
with the Pennsylvania Secretary of State on July
23, 1991 (Incorporated by reference to Exhibit
4.1(b) to the Company's Report on Form 10-Q for
the quarter ended June 30, 1991).
3.1(c) Amendment to the Second Amended and Restated
Articles of Incorporation, as filed with the
Pennsylvania Secretary of State on November 1,
1991. (Incorporated by reference to Exhibit 4.1(c)
to the Company's Report on Form 10-Q for the
quarter ended September 30, 1991).
3.1(d) Amendment to the Second Amended and Restated
Articles of Incorporation, as filed with the
Pennsylvania Secretary of State on February 12,
1993. (Incorporated by reference to Exhibit 4.1(d)
to the Company's Report on Form 10-Q for the
quarter ended December 31, 1992).
3.2 Amended and Restated By-Laws of Alkermes, Inc.,
effective as of July 1, 1994. (Incorporated by
reference to Exhibit 4.2 to the Company's Report
on Form 10-Q for the quarter ended June 30, 1994).
4.1 Specimen of Common Stock Certificate of Alkermes,
Inc. (Incorporated by reference to Exhibit 4 to
the Company's Registration Statement on Form S-1,
as amended (File No. 33-40250)).
4.2 Form of 1992 Warrant to purchase 2,800 shares of
the Company's Common Stock. (Incorporated by
reference to Exhibit 4.2 to the Company's Report
on Form 10-K for the fiscal year ended March 31,
1992).
4.3 Form of 1995 Warrant to purchase 300 shares of the
Company's Common Stock. (Incorporated by reference
to Exhibit 4.3 to the Company's Report on Form
10-K for the fiscal year ended March 31, 1992).
4.4 Form of Global Warrant Certificate for 1994 Class
A Warrants. (Incorporated by reference to Exhibit
4.6 to the Company's Report on Form 10-Q for the
quarter ended December 31, 1994).
(12)
<PAGE> 13
NUMBER EXHIBIT
------ -------
4.5 Form of Global Warrant Certificate for 1994 Class
B Warrants. (Incorporated by reference to Exhibit
4.7 to the Company's Report on Form 10-Q for the
quarter ended December 31, 1994).
4.6 Form of Global Warrant Certificate for 1994
Affiliate Warrants. (Incorporated by reference to
Exhibit 4.8 to the Company's Report on Form 10-Q
for the quarter ended December 31, 1994).
4.7 Form of Global Warrant Certificate for 1994
Incentive Warrants. (Incorporated by reference to
Exhibit 4.9 to the Company's Report on Form 10-Q
for the quarter ended December 31, 1994).
4.8 Warrant Agreement, dated as of November 18, 1994,
by and between the Company and The First National
Bank of Boston. (Incorporated by reference to
Exhibit 4.10 to the Company's Report on Form 10-Q
for the quarter ended December 31, 1994).
11 Statement regarding computation of per share loss.
27 Financial Data Schedule.
(b) The Registrant filed a report on Form 8-K dated March 31, 1997 under Item 5
on April 3, 1997.
(13)
<PAGE> 14
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
ALKERMES, INC.
(Registrant)
Date: August 13, 1997 By: /s/ Richard F. Pops
----------------------
Richard F. Pops
Chief Executive Officer and
Director
(Principal Executive Officer)
Date: August 13, 1997 By: /s/ Michael J. Landine
-------------------------
Michael J. Landine
Senior Vice President, Chief
Financial Officer and Treasurer
(Principal Financial and
Accounting Officer)
(14)
<PAGE> 15
EXHIBIT INDEX
EXHIBIT
NUMBER DESCRIPTION
------- -----------
3.1(a) Second Amended and Restated Articles of
Incorporation, as filed with the Pennsylvania
Secretary of State on July 23, 1991 (Incorporated
by reference to Exhibit 4.1(a) to the Company's
Report on Form 10-Q for the quarter ended June 30,
1991).
3.1(b) Statement of Change of Registered Office, as filed
with the Pennsylvania Secretary of State on July
23, 1991 (Incorporated by reference to Exhibit
4.1(b) to the Company's Report on Form 10-Q for
the quarter ended June 30, 1991).
3.1(c) Amendment to the Second Amended and Restated
Articles of Incorporation, as filed with the
Pennsylvania Secretary of State on November 1,
1991. (Incorporated by reference to Exhibit 4.1(c)
to the Company's Report on Form 10-Q for the
quarter ended September 30, 1991).
3.1(d) Amendment to the Second Amended and Restated
Articles of Incorporation, as filed with the
Pennsylvania Secretary of State on February 12,
1993. (Incorporated by reference to Exhibit 4.1(d)
to the Company's Report on Form 10-Q for the
quarter ended December 31, 1992).
3.2 Amended and Restated By-Laws of Alkermes, Inc.,
effective as of July 1, 1994. (Incorporated by
reference to Exhibit 4.2 to the Company's Report
on Form 10-Q for the quarter ended June 30, 1994).
4.1 Specimen of Common Stock Certificate of Alkermes,
Inc. (Incorporated by reference to Exhibit 4 to
the Company's Registration Statement on Form S-1,
as amended (File No. 33-40250)).
4.2 Form of 1992 Warrant to purchase 2,800 shares of
the Company's Common Stock. (Incorporated by
reference to Exhibit 4.2 to the Company's Report
on Form 10-K for the fiscal year ended March 31,
1992).
4.3 Form of 1995 Warrant to purchase 300 shares of the
Company's Common Stock. (Incorporated by reference
to Exhibit 4.3 to the Company's Report on Form
10-K for the fiscal year ended March 31, 1992).
(15)
<PAGE> 16
EXHIBIT
NUMBER DESCRIPTION
------- -----------
4.4 Form of Global Warrant Certificate for 1994 Class
A Warrants. (Incorporated by reference to Exhibit
4.6 to the Company's Report on Form 10-Q for the
quarter ended December 31, 1994).
4.5 Form of Global Warrant Certificate for 1994 Class
B Warrants. (Incorporated by reference to Exhibit
4.7 to the Company's Report on Form 10-Q for the
quarter ended December 31, 1994).
4.6 Form of Global Warrant Certificate for 1994
Affiliate Warrants. (Incorporated by reference to
Exhibit 4.8 to the Company's Report on Form 10-Q
for the quarter ended December 31, 1994).
4.7 Form of Global Warrant Certificate for 1994
Incentive Warrants. (Incorporated by reference to
Exhibit 4.9 to the Company's Report on Form 10-Q
for the quarter ended December 31, 1994).
4.8 Warrant Agreement, dated as of November 18, 1994,
by and between the Company and The First National
Bank of Boston. (Incorporated by reference to
Exhibit 4.10 to the Company's Report on Form 10-Q
for the quarter ended December 31, 1994).
11 Statement regarding computation of per share loss.
27 Financial Data Schedule.
(16)
<PAGE> 1
EXHIBIT 11
STATEMENT REGARDING COMPUTATION OF PER SHARE
LOSS
<TABLE>
<CAPTION>
Three Months Three Months
Ended Ended
June 30, 1997 June 30, 1996
------------- -------------
<S> <C> <C>
Net loss $ (4,027,732) $ (4,943,991)
============ ============
Calculation of shares outstanding:
Weighted average common shares outstanding used in calculating net loss
per share in accordance with generally accepted accounting
principles 20,752,848 17,325,561
------------ ------------
Total 20,742,848 17,325,561
============ ============
Net loss per share $ (0.19) $ (0.29)
============ ============
</TABLE>
<TABLE> <S> <C>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE 10-Q FOR
THE THREE MONTHS ENDED JUNE 30, 1997 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> MAR-31-1998
<PERIOD-START> APR-01-1997
<PERIOD-END> JUN-30-1997
<CASH> 4,016
<SECURITIES> 81,630
<RECEIVABLES> 0
<ALLOWANCES> 0
<INVENTORY> 0
<CURRENT-ASSETS> 89,922
<PP&E> 16,893
<DEPRECIATION> (8,018)
<TOTAL-ASSETS> 101,182
<CURRENT-LIABILITIES> 6,901
<BONDS> 12,210
0
0
<COMMON> 208
<OTHER-SE> 75,240
<TOTAL-LIABILITY-AND-EQUITY> 101,182
<SALES> 0
<TOTAL-REVENUES> 5,931
<CGS> 0
<TOTAL-COSTS> 7,608
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 437
<INCOME-PRETAX> (4,028)
<INCOME-TAX> 0
<INCOME-CONTINUING> (4,028)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (4,028)
<EPS-PRIMARY> (0.19)
<EPS-DILUTED> (0.19)
</TABLE>
